RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has secured a $14 million credit facility with Hercules Technology II, L.P., an affiliate of Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC). PolyMedix expects that proceeds from the facility may be used to fund certain Phase 3 enabling activities for its two lead compounds, PMX-60056 and PMX-30063, including manufacturing and toxicology studies, and for other general corporate purposes.
